###begin article-title 0
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer
###end article-title 0
###begin p 1
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
See related research by Ljuslinder et al., 
###end p 1
###begin title 2

###end title 2
###begin p 3
###xml 19 27 19 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Using fluorescence in situ hybridization (FISH), we previously showed that the LRIG1 gene had an increased copy number in 11 of 28 (39%) breast cancer tumours [1]. The LRIG1 gene (leucine-rich repeats and immunoglobulin-like domains 1) at chromosome 3p14 is a proposed tumour suppressor gene that negatively regulates various receptor tyrosine kinases, including the breast cancer proto-oncogene product ERBB2 [2,3].
###end p 3
###begin p 4
###xml 42 43 42 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 77 79 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 440 446 440 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 503 509 503 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 513 519 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 558 564 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 611 617 611 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 764 770 764 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 778 779 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 869 875 869 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 904 910 904 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 969 970 969 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
Recently, however, Miller and colleagues [4] showed that 10 of 13 (76%) ERBB2+ tumours had decreased LRIG1 protein levels compared to normal breast tissue. As their data showed down-regulation at the protein level whereas our data showed an increased copy number at the genomic level, we analysed 45 additional breast tumours by FISH as previously described [1]. Thus, out of 73 tumours analysed to date, 25 (34%) did indeed have increased LRIG1 copy number. To further analyse the relationship between LRIG1 and ERBB2 at the genomic level, we evaluated the ERBB2 gene copy numbers in 18 tumours with increased LRIG1 copy number using FISH analysis according to standard procedures. Interestingly, 16 (89%) out of the 18 tumours displayed increased copy number of ERBB2 (Figure 1). This suggests that the majority of breast cancer tumours with increased copy number of ERBB2 simultaneously had increased LRIG1 copy number (our data) and decreased LRIG1 protein levels [4].
###end p 4
###begin p 5
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Increased copy number of <italic>LRIG1 </italic>and <italic>ERBB2 </italic>in human breast cancer in the same patient</bold>
###xml 154 158 154 158 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 169 175 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 204 210 204 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 340 344 340 344 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 355 361 355 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 401 407 401 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 76 83 <span type="species:ncbi:9606">patient</span>
Increased copy number of LRIG1 and ERBB2 in human breast cancer in the same patient. Interphase nuclei from a breast cancer tumour were analysed by FISH. (a) A specific LRIG1 probe (red) showed increased LRIG1 copy number (five copies) whereas a specific centromere probe (CEP3) (green) showed normal chromosome 3 copy number (two copies). (b) A specific ERBB2 probe (red) showed amplification of the ERBB2 gene whereas a specific centromere probe (CEP17; green) showed three copies of chromosomes 17.
###end p 5
###begin p 6
###xml 149 155 149 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1</italic>
###xml 331 337 331 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 491 497 491 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 751 752 751 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 819 825 819 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
###xml 1073 1079 1073 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se</italic>
We draw the following major conclusions from these results. First, as previously shown, a significant proportion of breast tumours have an increased LRIG1 gene dosage. Second, there is a correlation between increased gene copy numbers of ERBB2 and LRIG1. Third, based on the Miller protein data, most of the tumours with increased LRIG1 gene dosage express reduced levels of the LRIG1 protein. This indicates a negative selection against LRIG1 protein expression, supporting the notion that LRIG1 is a tumour suppressor in breast cancer. Although the mechanism behind the down-regulation of LRIG1 protein in breast cancer is not known, it has been reported that increased gene copy numbers in some cases are associated with decreased mRNA expression [5]. In any case, the high frequency (34%) of tumours with increased LRIG1 gene copy number implies a positive selection for tumour cells with this genomic alteration. It remains, however, to be elucidated whether the molecular driver behind the selective advantage associated with this alteration is LRIG1 down-regulation per se. Other possibilities include activation of nearby proto-oncogenes or the generation of novel oncogenic fusion genes.
###end p 6
###begin p 7
###xml 57 63 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRIG1 </italic>
In summary, the co-incidental increase in copy number of ERBB2 and LRIG1 in breast cancer is a novel finding, pointing at a functional co-operation between these genetic events, where the biological and clinical importance need to be clarified further.
###end p 7
###begin title 8
Abbreviations
###end title 8
###begin p 9
###xml 19 27 19 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
FISH: fluorescence in situ hybridization.
###end p 9
###begin title 10
Competing interests
###end title 10
###begin p 11
The authors declare that they have no competing interests.
###end p 11
###begin article-title 12
Increased copy number at 3p14 in breast cancer
###end article-title 12
###begin article-title 13
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation
###end article-title 13
###begin article-title 14
The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases
###end article-title 14
###begin article-title 15
Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer
###end article-title 15
###begin article-title 16
Relative impact of nucleotide and copy number variation on gene expression phenotypes
###end article-title 16

